Edgewise Therapeutics (EWTX) Research & Development (2020 - 2026)

Edgewise Therapeutics has reported Research & Development for 7 years, with the latest figure at $42.7 million in Q1 2026.

• Quarterly Research & Development rose 16.04% year-over-year to $42.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157.3 million (up 15.62% YoY) and the FY2025 annual result came in at $151.4 million, up 19.24% from the prior year.
• Research & Development slipped to $42.7 million in Q1 2026 per EWTX's latest filing, from $43.6 million in the prior quarter.
• Over five years, Research & Development peaked at $43.6 million in Q4 2025 and troughed at $11.1 million in Q1 2022.
• A 5-year average of $27.4 million and a median of $27.7 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 107.54% in 2022, then increased 9.38% in 2025.
• Over 5 years, Research & Development stood at $16.6 million in 2022, then jumped by 66.65% to $27.7 million in 2023, then jumped by 31.38% to $36.4 million in 2024, then climbed by 19.86% to $43.6 million in 2025, then retreated by 2.16% to $42.7 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $42.7 million, $43.6 million, and $37.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.